Table 1.

Demographic and clinical characteristics of the 103 vertigo patients included in the study.

Variables	All Patients n = 103	Central n = 24	Nonspecific n = 79	p-Value
Median age at diagnosis,				0.794
years (IQR)	60 (49–69)	61 (48–69)	60 (49–69)
Gender				* 0.014
Female	65 (63.1%)	10 (41.7%)	55 (69.6%)
Male	38 (36.9%)	14 (58.3%)	24 (30.4%)
Body mass index (n = 99)				0.339
Median (IQR)	24.0 (21.7–25.7)	24.7 (22.5–26.6)	23.8 (21.7–25.7)
Asymmetric hearing loss (n = 85)				0.379
No	71 (83.5%)	11 (91.7%)	60 (82.2%)
Yes (>30 dB loss)	14 (16.5%)	1 (8.3%)	13 (17.8%)
Neurologic symptoms				* <0.001
No	78 (75.7%)	8 (33.3%)	70 (88.6%)
Yes	25 (24.3%)	16 (66.7%)	9 (11.4%)
Central lesions (MRI)		N/A	N/A
No	79 (76.7%)
Yes	24 (23.3%)
Lesion sites (MRI)		N/A	N/A
Cortical and subcortical	10 (38.5%)
Brain stem	10 (38.5%)
Cerebellar	5 (19.2%)
Skull base	1 (3.8%)
Lesion types (MRI)		N/A	N/A
Cerebrovascular accident	13 (54.2%)
Tumor	9 (37.5%)
Inflammation	2 (8.3%)
Comorbidities
Diabetes mellitus				0.556
No	83 (80.6%)	18 (75.0%)	65 (82.3%)
Yes	20 (19.4%)	6 (25.0%)	14 (17.7%)
Hypertension				0.323
No	52 (50.5%)	10 (41.7%)	42 (53.2%)
Yes	51 (49.5%)	14 (58.3%)	37 (46.8%)
Hyperlipidemia				0.253
No	66 (64.1%)	13 (54.2%)	53 (67.1%)
Yes	37 (35.9%)	11 (45.8%)	26 (32.9%)
History of CVA				0.622
No	97 (94.2%)	22 (91.7%)	75 (94.9%)
Yes	6 (5.8%)	2 (8.3%)	4 (5.1%)
Cardiovascular disease				0.588
No	98 (95.2%)	24 (100.0%)	74 (93.7%)
Yes	5 (4.8%)	0 (0.0%)	5 (6.3%)
Accumulated comorbidities				0.709
0	28 (27.2%)	5 (20.8%)	23 (29.1%)
1–2	64 (62.1%)	16 (66.7%)	48 (60.8%)
≥3	11 (10.7%)	3 (12.5%)	8 (10.1%)

* p < 0.05. Abbreviations: CVA, cerebrovascular accident; IQR, interquartile range; N/A, not applicable.